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Abstract In cultured vascular smooth muscle cells (VSMCs), 
angiotensin II (Ang II) stimulated tyrosine phosphorylation of 
several proteins including a cluster of 70-80-kDa proteins as 
assessed by anti-phosphotyrosine immunoblotting. These 70-80- 
kDa proteins were identified as a focal adhesion-associated pro- 
tein, paxillin, by anti-paxillin immunoprecipitation. Ang II-stimu- 
lated tyrosine phosphorylation of paxillin was detectable within 
1 rain and maximal at around 10 rain and was concentration 
dependent (half-maximal effect at around 1 nM). Ang II also 
stimulated tyrosine phosphorylation of focal adhesion kinase in 
a time- and concentration-dependent manner. The Ang II type 1 
(AT1) receptor antagonist, CV-11974, but not the Ang II type 2 
receptor antagonist, PD123319, inhibited these reactions. These 
results indicate that Ang I! transduces its signal to focal adhe- 
sions via AT1 receptors in cultured VSMCs. 
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1. Introduction 
Angiotensin II (Ang II), a potent vasoconstrictor, plays a 
pivotal role in the genesis of various vascular lesions which are 
characterized by vascular smooth muscle cell (VSMC) growth 
such as vascular emodeling due to chronic hypertension and 
myointimal proliferation following balloon angioplasty [1,2]. In 
a cell culture system, Ang II stimulates either hypertrophic [3] 
or hyperplastic [4,5] growth of VSMCs depending on the condi- 
tions. Ang II also has been shown to stimulate VSMC migra- 
tion which is considered to play a major role in the genesis of 
intimal thickening following balloon angioplasty [6]. Although 
Ca ~+, calmodulin-dependent phosphorylation of myosin light 
chain is thought o play a critical role in VSMC contraction, 
molecular mechanisms responsible for growth-promoting and 
cell-migrating actions of Ang II have not been fully understood. 
Recently, several investigators have shown that Ang II stimu- 
lates tyrosine phosphorylation of intracellular proteins in 
VSMCs [7,8]. In past immunoblot experiments with anti- 
phosphotyrosine antibody, Ang II induces tyrosine phospho- 
rylation of proteins with apparent molecular masses of 190, 
100-120, 70-80, 45 and 40 kDa in VSMCs [7]. The 45- and 
40-kDa proteins have been identified as mitogen-activated pro- 
tein kinase isozymes [9]. These may be involved in the signaling 
mechanism from the Ang II receptor to the nucleus and play 
crucial roles in the growth-promoting action of Ang II. How- 
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ever, other proteins which are tyrosine-phosphorylated in re- 
sponse to Ang II have not been identified. 
Focal adhesions are discrete regions of the plasma membrane 
in which the actin cytoskeleton is linked to the extracellular 
matrix via several cytoskeleton and membrane proteins. Focal 
adhesions are thought to play a central role in the processes that 
regulate cell adhesion, motility and proliferation [10]. Among 
a variety of proteins that localize to focal adhesions, paxillin is 
a 68-kDa protein which binds to vinculin, an actin-capping 
protein [11]. Paxillin has been shown to be tyrosine- 
phosphorylated during cell adhesion to the extracellular matrix 
[12] or in cells transformed by Rous sarcoma virus [13]. This 
suggests that tyrosine phosphorylation of paxillin may be in- 
volved in regulating functions of focal adhesions. 
Recently, Rozengurt and his colleagues have shown that 
paxillin is tyrosine-phosphorylated in Swiss 3T3 cells stimu- 
lated with mitogenic neuropeptides such as bombesin, vaso- 
pressin or endothelin [14]. Since Ang II and these neuropeptides 
share the same intracellular signaling pathway including a rapid 
hydrolysis of phosphoinositides, the present study examined 
whether the 70-80-kDa proteins which were tyrosine- 
phosphorylated in response to Ang II may be paxillin. This 
report shows that these tyrosine-phosphorylated 70-80-kDa 
proteins are indeed paxillin and that Ang II stimulates paxillin 
tyrosine phosphorylation viaAng II type 1 (AT1) receptors. 
Evidence is also provided that Ang II stimulates tyrosine phos- 
phorylation of focal adhesion kinase (FAK), a cytosolic tyro- 
sine kinase which localizes to focal adhesions and may play an 
important role in the formation of focal adhesions and the actin 
cytoskeleton [15]. This report provides the first demonstration 
that Ang II transduces its signal to focal adhesions in VSMCs, 
one of the most important target cells of this peptide. 
2. Materials and methods 
2.1. Materials 
VSMCs were isolated from rat thoracic aorta by enzymatic dissocia- 
tion as described previously [7] and used at passage l vels 8-16. Ang 
II and cytochalasin D were obtained from Sigma (St.Louis, MO, USA). 
The AT1 receptor antagonist, CV-11974, and the Ang II type 2 (AT2) 
receptor antagonist, PD123319, were gifts from Takeda Pharmaceuti- 
cal Co., Ltd. (Osaka, Japan) and Parke-Davis, Warner-Lambert Co. 
(Ann Arbor, MI, USA), respectively. Mouse anti-phosphotyrosine 
monoclonal ntibody (IgM) was prepared as described [7]. Mouse anti- 
paxillin and anti-FAK monoclonal antibodies were obtained from 
Transduction Laboratories (Lexington, KY, USA). Sheep anti-mouse 
IgG conjugated with peroxidase and goat anti-mouse IgM conjugated 
with peroxidase were from Amersham Life Science (Tokyo, Japan) and 
Cappel (West Chester, PA, USA), respectively. Protein A-Sepharose 
4FF was from Pharmacia (Uppsala, Sweden). Affinity-purified rabbit 
anti-mouse IgG was from Jackson ImmunoResearch Laboratories, Inc. 
All rights reserved. 
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(West Grove, PA, USA). Other materials and chemicals were obtained 
from commercial sources. 
2.2. Preparation of cell extracts and immunoprecipitates 
Whole cell extracts were prepared as described previously [7] except 
that the lysis buffer containing 50 mM Hepes, 1% Triton X-100, 50 mM 
NaCl, 50 mM NaF, 10 mM sodium pyrophosphate, 5 mM ethylenedi- 
aminetetraacetic acid, 1 mM sodium orthovanadate, 1 mM phen- 
ylmethylsulfonyl fluoride, 100 kallikrein-inactivating U/ml of aprotinin 
and 20/~M leupeptin, pH 7.5 was used for FAK immunoprecipitation. 
They were normalized to protein content (Bio Rad) and divided into 
two parts. One was directly added to a 114 vol. 5 x sodium dodecyl 
sulfate (SDS) sample buffer of Laemmli [16] and boiled at 100°C for 
5 rain. The other was added to either 1/zg anti-paxillin antibody or 2 pg 
anti-FAK antibody per 250/~g total proteins and rotated at 4°C over- 
night. Immunocomplexes were immunoprecipitated for 1 h at 4°C with 
Sepharose A-linked anti-mouse IgG. Immunoprecipitates w re washed 
three times with lysis buffer, extracted in 100/zl 1 x SDS sample buffer 
of Laemmli, and boiled at 100°C for 5 min. 
2.3. Immunoblot analysis' 
Whole cell extracts and paxillin or FAK immunoprecipitates w re 
subjected to SDS-polyacrylamide gelelectrophoresis (8-16% gradient 
gel). Each lane corresponded to 150/lg of the cell extract or the im- 
munoprecipitate from 150/lg (paxillin) or 200 ,ug (FAK) of total pro- 
teins. The separated proteins were electrophoretically transferred to 
nitrocellulose membranes. Immunoblot analysis was performed as de- 
scribed previously [7] except hat peroxidase-labeled sheep anti-mouse 
IgG was used as a second antibody for immunoblot analyses with 
anti-paxillin antibody or anti-FAK antibody. Stained protein bands 
were scanned with a Shimadzu Dual-Wavelength TLC Scanner CS-930 
for quantification. 
2.4. Statistics 
Results of densitometric analysis are presented as mean + standard 
error of the mean (S.E.M.). Differences between means were evaluated 
by t-test where appropriate. A value ofP < 0.05 was taken to be signif- 
icant. 
3. Results 
As has been reported previously [7], Ang II stimulated tyro- 
sine phosphorylation f several proteins in VSMCs as assessed 
by anti-phosphotyrosine immunoblotting of whole cell extracts 
(Fig. 1A, lanes 1,2). To examine whether a cluster of 70-80-kDa 
proteins which were most heavily stained were related to pax- 
illin, immupoprecipitation analysis with anti-paxillin antiboby 
was performed (Fig. 1A, lanes 3-6). All of the tyrosine- 
phosphorylated 70-80-kDa proteins were immunoprecipitated 
with anti-paxillin antibody. Ang II caused a striking increase 
in tyrosine phosphorylation of anti-paxillin immunoprecipita- 
ble bands (Fig. 1A, lanes 3,4). Parallel immunoblots with anti- 
paxillin antibody verified that similar amounts of paxillin were 
immunoprecipitated from VSMCs treated with or without Ang 
II (Fig. 1B). Based upon these results, it was concluded that 
most of a cluster of 70-80-kDa proteins which were tyrosine- 
phosphorylated in response to Ang II were paxillin. A diffuse 
band on reduced SDS gels may be due to its multiply 
phosphorylated forms. 
Although the basal evel of paxillin tyrosine phosphorylation 
somewhat differed from experiment to experiment, Ang II con- 
sistently stimulated this reaction. Ang II-stimulated paxillin 
phosphorylation was detected within 1 min after the addition 
of Ang II, reached a maximum at around 10 min and then 
declined slowly (Fig. 2A). Ang II-stimulated paxillin phospho- 
rylation was concentration dependent with half-maximum and 
maximum effects obtained at around 1 and 100 nM, respec- 
tively (Fig. 2B). [mmunoblotting with anti-paxillin antibody 
confirmed that similar amounts of paxillin were recovered after 
different imes and concentrations of Ang II treatment (data 
not shown). 
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Fig. 1. Ang II-stimulated tyrosine phosphorylation f paxillin. Cultured VSMCs were treated without (lanes 1,3,5) or with 100 nM Ang II (lanes 
2,4,6) for 5 min at 37°C. Cell extracts were subjected to immunoprecipitation analysis with anti-paxillin antibody. Whole cell extracts (lanes 1,2), 
paxillin immunoprecipitates (lanes 3,4) and supernatants after immunoprecipitation (la es 5,6) were analyzed by immunoblotting with anti- 
phosphotyrosine (A)or anti-paxillin antibody (B). The experiment shown represents one of three independent trials which gave nearly identical results. 
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(Fig. 4A). The concentrations of Ang II required for the stim- 
ulation of FAK tyrosine phosphorylation were roughly the 
same as those required for the stimulation of paxillin tyrosine 
phosphorylation (Fig. 4B). Ang II-stimulated tyrosine phos- 
phorylation of FAK was also inhibited by CV-11974 but not 
by PD123319 (Fig. 5). Both antagonists by themselves had no 
effect on FAK tyrosine phosphorylation (data not shown). 
4. Discussion 
The results of the present study clearly demonstrated that 
Ang II stimulated tyrosine phosphorylation of paxillin and 
FAK via AT1 receptors in VSMCs. The precise nature of the 
signaling mechanisms involved have not yet been elucidated. 
Since the ATl-receptor is coupled to phospholipase C-medi- 
ated phosphoinositide hydrolysis [18], it is possible that 
this signaling pathway is involved in the stimulatory effect of 
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Fig. 2. Time- and concentration-dependent increase of Ang II-stimu- 
lated tyrosine phosphorylation of paxillin. Cultured VSMCs were 
treated for various times with 100 nM Ang II at 37°C (A) or treated 
for 5 min at 37°C with various concentrations of Ang II as indicated 
(B). Tyrosine-phosphorylated paxiUin was analyzed by immunoblot- 
ting of anti-paxillin mmunoprecipitates with anti-phosphotyrosine a - 
tibody. Quantification fphosphorylation was performed by scanning 
densitometry. Values hown are the mean + S.E.M. of four independ- 
ent trials and are expressed asthe percentage of the control unstimu- 
lated levels. *P < 0.05 vs control. 
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Ang II receptors have been classified into AT1 and AT2 
subtypes [17]. Ang II-stimulated tyrosine phosphorylation f 
paxillin was completely inhibited by the AT1 receptor antago- 
nist, CV-11974, but not by the AT2 receptor antagonist, 
PD123319 (Fig. 3). Both antagonists by themselves had no 
effect on this reaction (data not shown). These results indicate 
that Ang II stimulates paxillin tyrosine phosphorylation via 
AT1 receptors. 
In the last set of experiments, it was examined whether Ang 
II stimulated tyrosine phosphorylation f FAK. Ang II rapidly 
stimulated tyrosine phosphorylation f FAK as assessed by 
anti-phosphotyrosine immunoblotting of anti-FAK im- 
munoprecipitates. An increase was detected within 1 min after 
the addition of Ang II and reached a maximum within 5 min 
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Fig. 3. AT1 receptor-mediated stimulation of paxillin tyrosine phos- 
phorylation. Cultured VSMCs were preincubated without (lanes 1,2) 
or with 100 nM CV-11974 (lane 3) or 100 nM PD123319 (lane 4) for 
2 min at 37°C. Cells were subsequently treated without (lane 1) or with 
100 nM Ang II for 5 min (lanes 24). Paxillin was analyzed by im- 
munoblotting of anti-paxillin mmunoprecipitates withanti-phosphoty- 
rosine antibody (P-Tyr Ab) or anti-paxillin antibody (paxillin Ab) (A). 
The experiment shown represents one of three independent trials which 
gave nearly identical results. The bar graph shows densitometric analy- 
sis of paxillin tyrosine phosphorylation (B). Values shown are the 
mean _+ S.E.M. of three independent trials and are expressed as the 
percentage of the control unstimulated levels. *P < 0.05 vs control. 
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Fig. 4. Time- and concentration-dependent increase of Ang II-stimu- 
lated tyrosine phosphorylation f FAK. Cultured VSMCs were treated 
for various times with 100 nM Ang II at 37°C (A) or treated for 2 min 
at 37°C with various concentrations of Ang II as indicated (B). Tyro- 
sine-phosphorylated FAK was analyzed by immunoblotting of anti- 
FAK immunoprecipitates with anti-phosphotyrosine a tibody. Quan- 
tification of phosphorylation was performed by scanning densitometry. 
Values hown are the mean + S.E.M. of three independent trials and 
are expressed as the percentage of the control unstimulated levels. 
*P < 0.05 vs control. 
Ang II on tyrosine phosphorylation f paxillin and FAK. In 
agreement with this possibility, other vasoconstrictors, such as 
vasopressin, 5-hydroxytryptamine, orepinephrine and endo- 
thelin-1 which also cause phosphoinositide hydrolysis, stimu- 
lated tyrosine phosphorylation f paxillin as judged by im- 
munoblotting with anti-phosphotyrosine a tibody of whole cell 
extracts [7,19]. On the other hand, Zachary et al. [14,20] re- 
ported that cytochalasin D, an agent hat selectively disrupts 
the network of actin microfilaments, completely inhibited 
bombesin-induced tyrosine phosphorylation of paxillin and 
FAK in Swiss 3T3 cells. Rho p21 is a member of the ras super- 
family of small GTP-binding proteins and has been implicated 
in the regulation of the actin cytoskeleton [21]. It has been 
reported that the Clostridium botulinum C3 exoenzyme pre- 
treatment, which inactivates rho p21 by ADP ribosylation [22], 
suppressed bombesin- and endothelin-induced tyrosine phos- 
phorylation of paxillin and FAK in Swiss 3T3 cells [23]. Pre- 
treatment of VSMCs with either cytochalasin D or C3 exoen- 
zyme also inhibited Ang II-induced paxillin tyrosine phospho- 
rylation in our system (data not shown). These observations 
suggest hat the integrity of the actin cytoskeleton may be 
essential for and rho p21 may be involved in the signaling 
mechanisms from the AT1 receptor as well as the bombesin 
receptor to focal adhesions. 
Previously, we reported that Ang II caused tyrosine phos- 
phorylation of proteins with molecular masses of 190, 100-120, 
70-80 (paxillin), 45 and 40 kDa (MAP kinases) in VSMCs [7]. 
We investigated whether there were any proteins tyrosine- 
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Fig. 5. AT1 receptor-mediated stimulation of FAK tyrosine phospho- 
rylation. Cultured VSMCs were preincubated without (lanes 1,2) or 
with 100 nM CV-11974 (lane 3) or 100 nM PD123319 (lane 4) for 2 min 
at 37°C. Cells were subsequently reated without (lane 1) or with 100 
nM Ang II for 2 min (lanes 24). FAK tyrosine phosphorylation a d 
amounts of FAK recovered after immunoprecipitation were analyzed 
by immunoblotting of anti-FAK immunoprecipitates with anti- 
phosphotyrosine antibody (P-Tyr Ab) and anti-FAK antibody (FAK 
Ab), respectively. The experiment shown represents one of three inde- 
pendent trials which gave nearly identical results. The bar graph shows 
densitometric analysis of FAK tyrosine phosphorylation (B). Values 
shown are the mean + S.E.M. of three independent trials and are ex- 
pressed as the percentage of the control unstimulated levels. *P < 0.05 
vs control. 
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phosphorylated in response to the AT2 receptor stimulation i  
VSMCs. As judged by immunoblotting with anti-phospho- 
tyrosine of whole cell extracts, however, tyrosine phosphoryla- 
tion of all of these proteins was not inhibited by the AT2 
receptor antagonist but by the ATI receptor antagonist, indi- 
cating that the AT2 receptor stimulation isnot involved in Ang 
II-induced tyrosine phosphorylation at least in our system. 
The physiological significance of tyrosine phosphorylation f 
paxillin and FAK is unknown at present. The localization of 
paxillin and its binding to vinculin suggest hat paxiUin has a 
potential role in the processes that regulate cell adhesion, motil- 
ity and proliferation via the rearrangement of the actin cy- 
toskeleton. Tyrosine phosporylation of FAK is also considered 
to be involved in regulating functions of focal adhesions [12]. 
Ang II-induced tyrosine phosphorylation of paxillin and/or 
FAK could be instrumental in triggering the assembly or disas- 
sembly of the actin cytoskeleton and contribute to growth pro- 
moting and/or cell migrating actions of Ang II. In VSMCs, 
paxillin also localizes to the dense plaques where the actin 
cytoskeleton i teracts with the surrounding extracellular ma- 
trix to transmit force generated uring muscle contraction 
across the membrane [24]. It has been suggested that the tran- 
sitory rearrangement of the actin filaments is involved in the 
tonic contraction of VSMCs [25]. Therefore, it is possible that 
via the rearrangement of the actin cytoskeleton, paxillin tyro- 
sine phosphorylation may play some role in the vasocon- 
stricting action of Ang II. Further studies are clearly needed to 
elucidate the roles of tyrosine phosphorylation f paxillin and 
FAK in various actions of Ang II. 
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